Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7669964 | 0.84 | MEN1 (0.39) | L3MBTL1KDM4CNPC1RAB9AMEN1 | |
| SCHEMBL5858706 | 0.84 | SLC6A3 (0.42) | L3MBTL1KDM4CNPC1RAB9AMEN1 | |
| SCHEMBL8971716 | 0.82 | L3MBTL1 (0.38) | L3MBTL1KDM4CNPC1RAB9AMEN1 | |
| SCHEMBL7674634 | 0.81 | L3MBTL1 (0.40) | L3MBTL1KDM4CNPC1RAB9AMEN1 | |
| SCHEMBL8364709 | 0.78 | MEN1 (0.40) | L3MBTL1KDM4CNPC1RAB9AMEN1 | |
| SCHEMBL7305306 | 0.77 | SLC6A3 (0.41) | L3MBTL1KDM4CNPC1RAB9AMEN1 | |
| SCHEMBL8368093 | 0.77 | TACR2 (0.44) | — | |
| SCHEMBL4263016 | 0.76 | L3MBTL1 (0.45) | L3MBTL1KDM4CNPC1RAB9AMEN1 | |
| SCHEMBL30076909 | 0.73 | L3MBTL1 (0.52) | L3MBTL1KDM4CNPC1RAB9AMEN1 | |
| SCHEMBL6579345 | 0.72 | SLC6A3 (0.45) | L3MBTL1KDM4CNPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6403601-B1 | TREATMENT OF ASTHMA, ANXIETY, DEPRESSION, EMESIS, URINARY INCONTINENCE AND RELATED CONDITIONS. | ASTRAZENECA AB (SE) | 2002-06-11 | — | — | US | disclosed |
| US-6365602-B1 | FOR THERAPY OF DEPRESSION, ANXIETY, ASTHMA, PAIN, INFLAMMATION, URINARY INCONTINENCE AND OTHER DISEASE CONDITIONS | ASTRA ZENECA AB (SE) | 2002-04-02 | — | — | US | disclosed |
| EP-1137637-A1 | N-(2-PHENYL-4-PIPERIDINYLBUTYL)-5,6,7,8-TETRAHYDRO-1-NAPHTHALENECARBOXAMIDES AND THEIR USE AS NEUROKININ 1 (NK1) AND/OR NEUROKININ 2 (NK2) RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2001-10-04 | — | — | EP | disclosed |
| EP-1097137-A1 | N-SUBSTITUTED NAPHTHALENE CARBOXAMIDES AS NEUROKININ-RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2001-05-09 | — | — | EP | disclosed |
| WO-2000034243-A1 | N-(2-PHENYL-4-PIPERIDINYBUTYL)-5,6,7,8-TETRAHYDRO-1-NAPHTHALENECARBOXAMIDES AND THEIR USE AS NEUROKININ 1 (NK1) AND/OR NEUROKININ 2 (NK2) RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2000-06-15 | — | — | WO | disclosed |
| WO-2000002859-A1 | N-SUBSTITUTED NAPHTHALENE CARBOXAMIDES AS NEUROKININ-RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2000-01-20 | — | — | WO | disclosed |
| US-5965580-A | TREATMENT OF SUBSTANCE P- AND NEUROKININ-DEPENDENT DISORDERS | SANOFI (FR) | 1999-10-12 | — | — | US | disclosed |
| US-5939411-A | PIPERIDINE DERIVATIVES SUBSTITUTED AT POSITION 4 WITH NEW FUNCTIONS OTHER THAN THOSE DESCRIBED PREVIOUSLY HAVE A HIGH AFFINITY FOR NEUROKININ RECEPTORS AND ARE USEFUL FOR TREATMENT OF SUBSTANCE P AND NEUROKININ DEPENDENT PATHOLOGIES | SANOFI (FR) | 1999-08-17 | — | — | US | disclosed |
| US-5830906-A | Piperidine derivatives, process for obtaining them and pharmaceutical compositions containing them | SANOFI (FR) | 1998-11-03 | — | — | US | disclosed |
| EP-0700382-A1 | NOVEL N-ARYLALIPHATIC-N-ALKYL-FUNCTIONALISED AMIDES, METHOD FOR THEIR PREPATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SANOFI (FR) | 1996-03-13 | — | — | EP | disclosed |
| WO-1995026335-A1 | NOVEL N-ARYLALIPHATIC-N-ALKYL-FUNCTIONALISED AMIDES, METHOD FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SANOFI (FR) | 1995-10-05 | — | — | WO | disclosed |